Lipid Microparticles Show Similar Efficacy With Lipid Nanoparticles in Delivering mRNA and Preventing Cancer
- 30 November 2022
- journal article
- research article
- Published by Springer Nature in Pharmaceutical Research
- Vol. 40 (1) , 265-279
Abstract
Purpose Messenger RNA (mRNA) has shown great promise for vaccine against both infectious diseases and cancer. However, mRNA is unstable and requires a delivery vehicle for efficient cellular uptake and degradation protection. So far, lipid nanoparticles (LNPs) represent the most advanced delivery platform for mRNA delivery. However, no published studies have compared lipid microparticles (LMPs) with lipid nanoparticles (LNPs) in delivering mRNA systematically, therefore, we compared the impact of particle size on delivery efficacy of mRNA vaccine and subsequent immune responses. Methods Herein, we prepared 3 different size lipid particles, from nano-sized to micro-sized, and they loaded similar amounts of mRNA. These lipid particles were investigated both in vitro and in vivo, followed by evaluating the impact of particle size on inducing cellular and humoral immune responses. Results In this study, all mRNA vaccines showed a robust immune response and lipid microparticles (LMPs) show similar efficacy with lipid nanoparticles (LNPs) in delivering mRNA and preventing cancer. In addition, immune adjuvants, either toll like receptors or active molecules from traditional Chinese medicine, can improve the efficacy of mRNA vaccines. Conclusions Considering the efficiency of delivery and endocytosis, besides lipid nanoparticles with size smaller than 150 nm, lipid microparticles (LMPs) also have the potential to be an alternative and promising delivery system for mRNA vaccines.Keywords
This publication has 60 references indexed in Scilit:
- Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responsesExpert Review of Vaccines, 2010
- Preformed portals facilitate dendritic cell entry into afferent lymphatic vesselsJournal of Experimental Medicine, 2009
- Lipid vesicle size of an oral influenza vaccine delivery vehicle influences the Th1/Th2 bias in the immune response and protection against infectionVaccine, 2009
- Enhancing the therapeutic efficacy of CpG oligonucleotides using biodegradable microparticlesAdvanced Drug Delivery Reviews, 2009
- Incorporation of Pseudouridine Into mRNA Yields Superior Nonimmunogenic Vector With Increased Translational Capacity and Biological StabilityMolecular Therapy, 2008
- Nanoparticles target distinct dendritic cell populations according to their sizeEuropean Journal of Immunology, 2008
- Potent Antigen-specific Immune Responses Stimulated by Codelivery of CpG ODN and Antigens in Degradable MicroparticlesJournal of Immunotherapy, 2007
- Influence of particle size, antigen load, dose and additional adjuvant on the immune response from antigen loaded PLA microparticlesInternational Journal of Pharmaceutics, 2005
- Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticlesVaccine, 2004
- The physiology of the lymphatic systemAdvanced Drug Delivery Reviews, 2001